🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Functional Impact at 12 Months Post-op of Posterior Cruciate Ligament Conservation During Robotic-assisted Surgery (MAKO) for Total Knee Replacement.

RecruitingNAAges 18 Years - anyAllCentre Hospitalier Universitaire de Nīmes
NCT07489963 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Studies have been made on the best way to do knee surgery and whether to conserve the posterior cruciate ligament or not during total knee prosthesis insertion is still under debate. However, most of these studies were made before the introduction of robotic knee surgery. It seems timely to do a study comparing these two surgical techniques: preservation versus removal of the posterior cruciate ligament in knee arthroplasty

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Patient scheduled for first-intention robotic-assisted total knee replacement (MAKO). * Unilateral replacement, regardless of laterality. * Patient able to answer questionnaires. * Patient willing to undergo usual 12-month follow-up. * Patient has given free and informed consent and has signed the consent form. * Patient affiliated with or benefiting from a health insurance scheme. Exclusion Criteria: * Patient with intraoperative technical impossibility of retaining PCL (flessum \> 20°, flexion stiffening \< 100°). * Previous posterior cruciate ligament surgery. * Post-traumatic gonarthrosis. * Valgus \> 185°. * Patient with septic complication. * Patient participating in another interventional trial. * Patient in an exclusion period determined by another study. * Patient under court protection, guardianship or curatorship. * Patient unable to give consent. * Patients for whom it is impossible to provide informed information. * Pregnant women
💊

What it tests

  • Total knee arthroplasty
📍

Where

3 sites
Clinique Tivoli-Ducos
Bordeaux, France
Hôpital Croix Rousse
Lyon, France
Nîmes University Hospital
Nîmes, France
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy